Expert Opinion: Optimum Clinical Approach to Combination-Use of SGLT2i + DPP4i in the Indian Diabetes Setting

• DOI: 10.1007/s13300-022-01219-x
• Publication Date: 2022-03-25T09:03:02Z
• Authors: Manoj Chadha; Ashok Kumar Das; Prasun Deb; Kalyan Kumar Gang...; Shashank Joshi; Jothydev Kesavadev; Rajiv Kovil; Surender Kumar; Anoop Misra; Viswanathan Mohan
• Keywords: Expert opinion

The Asian-Indian phenotype of type 2 diabetes mellitus is uniquely characterized for cardio-metabolic risk. In the context implementing patient-centric holistic risk management as a priority, choice various combinations antidiabetic agents should be individualized. Combined therapy with two classes agents, namely, dipeptidyl peptidase 4 inhibitors and sodium-glucose co-transporter-2 inhibitors, target several pathophysiological pathways. wide-ranging clinical outcomes associated this combination, including improvement glycemia adiposity, reduction metabolic vascular risk, safety, simplicity sustainable compliance, are extremely relevant to Asian Indian patient population living T2DM. review we describe available evidence in detail present rational practical guidance optimum use combination population.